IL33: Unlocking Its Potential as A Drug Target (G90865)

Target Name: IL33

NCBI ID: G90865

IL33

IL33: Unlocking Its Potential as A Drug Target

IL33 (Interleukin-33) is a cytokine that plays a crucial role in the regulation of cellular processes in various tissues, including the immune system, skin, and tissues of the nervous system. It is a high-endothelial venule-derived cytokine, which means that it is produced by endothelial cells in the walls of blood vessels.

IL33 has been shown to have a variety of functions, including the regulation of inflammation, the promotion of cell growth and differentiation, and the control of cell survival. It is a potent chemoattractant for immune cells, such as neutrophils, and has been shown to induce the migration of these cells to sites of infection or injury.

In addition to its role in immune regulation, IL33 has also been shown to be involved in several other cellular processes that are important for tissue repair and regeneration. It has been shown to promote the proliferation and migration of progenitor cells, which are responsible for the development and maintenance of tissues, and to regulate the production of new blood vessels.

IL33 has also been shown to play a role in the regulation of pain and inflammation. It has been shown to reduce the production of pain-sensitive ions, such as nitric oxide, and to inhibit the production of pro-inflammatory cytokines.

Despite these many functions, IL33 is still an untargeted drug. Researchers have identified several potential drug targets that could be targeted by small molecules or antibodies to modulate its activity. These include the modulation of its signaling pathways, the inhibition of its production, and the modulation of its levels in the body.

One potential drug target for IL33 is the inhibition of its production by the use of small molecules that can inhibit the activity of the nuclear factor NF-kappa-B, which is a transcription factor that plays a role in the regulation of IL33 production. These small molecules could include inhibitors of nuclear factor NF-kappa-B, such as Monsanto 111 (Pyrimidine) and Monsanto 112 (Pyrimidine), which have been shown to inhibit the activity of this transcription factor in cell culture.

Another potential drug target for IL33 is the inhibition of its import into cells, which would reduce its levels in the body. This could be achieved using antibodies that specifically recognize and bind to IL33, leading to its removal from the circulation and its subsequent degradation in the body.

IL33 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression. It has been shown to promote the migration of cancer cells to new sites of infection or injury, which could contribute to their spread and the development of new tumors.

In addition to its role in cancer progression, IL33 has also been shown to contribute to the regulation of cellular processes that are important for tissue repair and regeneration after injury or disease. It has been shown to promote the proliferation and migration of progenitor cells, which are responsible for the development and maintenance of tissues, and to regulate the production of new blood vessels.

Despite these many functions, IL33 is still an untargeted drug. Researchers have identified several potential drug targets that could be targeted by small molecules or antibodies to modulate its activity. These include the modulation of its signaling pathways, the inhibition of its production, and the modulation of its levels in the body.

In conclusion, IL33 is a highly interconnected cytokine that plays a critical role in the regulation of cellular processes in various tissues. Its production and regulation are tightly regulated, and its functions are diverse and complex. As such, it is an attractive drug target for the development of new therapies for a variety of diseases.

Protein Name: Interleukin 33

Functions: Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528). Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages

The "IL33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets